Investment Rating - The report assigns a positive investment rating, indicating a "Best-in-Class" potential for the company's product DB1311/BNT324 (B7H3 ADC) in treating late-line castration-resistant prostate cancer (CRPC) [3][9]. Core Insights - The latest efficacy and safety data for DB1311/BNT324 was presented at the 2026 ASCO Genitourinary Cancers Symposium, showcasing promising results in a Phase I/II clinical trial involving 104 patients [1][6]. - The median follow-up time was 9.2 months, with significant response rates: PSA50 response rate at 35.4%, confirmed overall response rate (ORR) at 34.5%, and disease control rate (DCR) at 87.9% [2][7]. - The median radiographic progression-free survival (rPFS) was reported at 11.3 months, with 6-month and 9-month rPFS rates of 72% and 63%, respectively [2][7]. - The safety profile was consistent with previous reports, primarily consisting of Grade 1-2 adverse events [2][7]. Summary by Sections Clinical Data - The clinical trial data included 104 patients, with 68 receiving 6 mg/kg Q3W treatment and 34 receiving 9 mg/kg Q3W treatment, and 53% of the patients were White [1][6]. - Among 82 evaluable patients, the median duration of response (DOR) was 10.2 months, indicating a strong survival benefit [2][7]. Comparative Analysis - The rPFS rate of 72% compares favorably against other treatments, such as Novartis' Lu177 and Johnson & Johnson's KLK2*CD3 TCE, which reported lower rPFS rates [3][9]. - The report highlights the potential of DB1311 to outperform existing therapies in terms of survival data, suggesting a strong competitive position in the market [3][9].
映恩生物-B：核心产品B7H3ADC前列腺癌数据披露，PFS数据优异-20260228